AR088729A1 - Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica - Google Patents

Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica

Info

Publication number
AR088729A1
AR088729A1 ARP120101017A ARP120101017A AR088729A1 AR 088729 A1 AR088729 A1 AR 088729A1 AR P120101017 A ARP120101017 A AR P120101017A AR P120101017 A ARP120101017 A AR P120101017A AR 088729 A1 AR088729 A1 AR 088729A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
methyl
halogen
carbamoyl
Prior art date
Application number
ARP120101017A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR088729A1 publication Critical patent/AR088729A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente se refiere a derivados de 3-ureidoisoquinolin-8-ilo de la fórmula (1) útiles en prevención o tratamiento de enfermedades bacterianas. Reivindicación 1: Un compuesto de la fórmula (1) en donde R¹ es alquilo C₁₋₃, haloalquilo C₂₋₃ o ciclopropilo; R² es H, halógeno, piridazin-4-ilo, pirimidin-5-ilo o un grupo que tiene la fórmula (2), (3) ó (4), en donde Rˣ es H y cada uno de Rʸ y Rᶻ es independientemente H o metilo, o cada uno de Rˣ y Rᶻ es H y Rʸ es halógeno, ciano, alquilo C₂₋₄, alcoxi C₁₋₄, amino, hidroxi, hidroxi-alquilo C₁₋₃, trifluorometilo, carbamoilo, carbamoil-alquilo C₁₋₂, (metilcarbamoil)-alquilo C₁₋₂, (dimetilcarbamoil)-alquilo C₁₋₂, terc-butoxicarbonilmetilo, ciclopropilo, pirrolidin-1-ilo, piperidin-1-ilo, morfolin-1-ilo o 1-morfolinometilo, o Rˣ es H y cada uno de Rʸ y Rᶻ es independientemente halógeno, o Rˣ es metilo, Rʸ es metilo o halógeno y Rᶻ es H, o Rˣ es metilo o halógeno, Rʸ es H y Rᶻ es metilo o halógeno, o Rˣ es metilo o halógeno y cada uno de Rʸ y Rᶻ es H; Rˣ² es H, amino o hidroximetilo; Rˣ³ es hidroxi, carboxi, carbamoilo, hidroximetilo o aminometilo, Rʸ³ es H y Rᶻ³ es H o cada uno de Rˣ³ y Rᶻ³ es H y Rʸ³ es hidroxi, acetamidometilo, (dimetilamino)metilo, carboximetilo, carbamoilo o aminometilo, o cada uno de Rˣ³ y Rʸ³ es H y Rᶻ³ es hidroxi; R³ es alquilo C₁₋₄, alquinilo C₂₋₄, amino-alquilo C₁₋₃, carbamoil-alquilo C₁₋₃, (metilcarbamoil)-alquilo C₁₋₃, alcoxi C₁₋₄, haloalcoxi C₁₋₄, alquiniloxi C₃₋₄, (4-hidroxibut-2-en-1-il)oxi, (4-aminobut-2-en-1-il)oxi, dimetilamino-alcoxi C₂₋₃, carbamoil-alcoxi C₁₋₃, alquilamino C₁₋₃, cicloalquilo C₃₋₆, cicloalquil C₃₋₆-alquilo C₁₋₄, cicloalquil C₃₋₆-alcoxi C₁₋₄, hidroxi-alquilo C₁₋₃, hidroxi-alcoxi C₂₋₃, alcoxi C₁₋₃-alquilo C₁₋₃, alcoxi C₁₋₃-alcoxi C₁₋₃, carboxi-alquilo C₁₋₃, carboxi-alcoxi C₁₋₃, alcoxicarbonil C₁₋₂-alcoxi C₁₋₃, arilo, heteroarilo C₅₋₆, bencilo, benciloxi, 2-cianoetoxi, 2,3-dihidroxipropoxi, 3,4-dihidroxibutoxi, -CH₂Rᵃ, -CH₂CH₂Rᵇ, -(CH₂)ₙ-C(O)O-Rᵈ, (CH₂)ₙ-N(Rᶜ)C(O)O-Rᵈ, -O-(CH₂)ₙ-N(Rᶜ)C(O)O-Rᵈ, -(CH₂)ₙ-Rᵉ o -O-(CH₂)ₙ-Rᵉ; n es 1, 2 ó 3; Rᵃ es ciano, acetilamino, N,N-dimetilamino; y Rᵇ es ciano; Rᶜ es H o metilo; Rᵈ es alquilo C₁₋₄; Rᵉ es pirrolidin-1-ilo, piperidin-1-ilo, piperidin-3-ilo, morfolin-1-ilo, 2-oxopirrolidin-1-ilo, 5-oxopirrolidin-2-ilo, 2,5-dioxopirrolidin-1-ilo, 2-oxoimidazoliden-1-ilo, 4-(terc-butoxicarbonil)piperazin-1-ilo, 4-(aminometil)ciclohexilo o heteroarilo C₅₋₆; R⁴ es H o metilo; o una sal de dicho compuesto.
ARP120101017A 2011-03-29 2012-03-27 Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica AR088729A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011051320 2011-03-29
IB2011054063 2011-09-16

Publications (1)

Publication Number Publication Date
AR088729A1 true AR088729A1 (es) 2014-07-02

Family

ID=45976978

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101017A AR088729A1 (es) 2011-03-29 2012-03-27 Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica

Country Status (16)

Country Link
US (1) US8889676B2 (es)
EP (1) EP2691373A1 (es)
JP (1) JP2014512352A (es)
KR (1) KR20140019423A (es)
CN (1) CN103476756A (es)
AR (1) AR088729A1 (es)
AU (1) AU2012235706A1 (es)
BR (1) BR112013024899A2 (es)
CA (1) CA2828423A1 (es)
IL (1) IL228486A0 (es)
MA (1) MA35048B1 (es)
MX (1) MX2013011253A (es)
RU (1) RU2013147875A (es)
TW (1) TW201249801A (es)
WO (1) WO2012131588A1 (es)
ZA (1) ZA201308049B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3604281A4 (en) 2017-03-24 2020-08-19 Taisho Pharmaceutical Co., Ltd. 2 (1H) -CHINOLINONE DERIVATIVE
KR20220127839A (ko) 2019-12-24 2022-09-20 항저우 종메이화동 파마슈티칼 컴퍼니 리미티드 Khk 억제 효과를 갖는 화합물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
AU6314900A (en) 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
NZ517706A (en) * 1999-10-08 2004-01-30 Affinium Pharm Inc Fab I inhibitors
DE60139964D1 (de) 2000-12-15 2009-10-29 Vertex Pharma Bakterielle Gyrase-Hemmer sowie deren Verwendung
US6831068B2 (en) 2002-02-13 2004-12-14 Abbott Laboratories Macrolide antibacterial compounds
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
WO2003105846A1 (en) * 2002-06-13 2003-12-24 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
EP1737459B1 (en) 2004-03-19 2009-08-05 Warner-Lambert Company LLC Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
MX2007004179A (es) 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
WO2006049941A2 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
CN1958568B (zh) * 2005-11-03 2011-04-13 中国科学院上海药物研究所 一类预防或治疗幽门螺杆菌感染化合物、其制法和用途
WO2007056330A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
DE102006029795A1 (de) * 2006-06-27 2008-01-03 Schebo Biotech Ag Neue Harnstoff-Derivate und deren Verwendungen
JP2010511682A (ja) 2006-12-04 2010-04-15 アストラゼネカ アクチボラグ 抗菌性の多環系尿素化合物
WO2008082487A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2008141010A2 (en) * 2007-05-11 2008-11-20 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
WO2009027732A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
WO2009027733A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
WO2009089083A1 (en) 2008-01-04 2009-07-16 Abbott Laboratories Trpa1 antagonists
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2009155121A2 (en) 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
MX2010013249A (es) 2008-06-04 2010-12-21 Astrazeneca Ab Derivados de tiazolo[5,4-b]piridina y oxazolo[5,4-b]piridina como agentes antibacterianos.
UY31864A (es) 2008-06-04 2010-01-29 Astrazeneca Ab Derivados de urea hetericíclica y métodos de uso de los mismos-332
CL2009001345A1 (es) 2008-06-04 2010-06-11 Astrazeneca Ab Compuestos derivados de 1-piridin-2-il-urea y 1-pirimidin-2-il-urea sustituidos, inhibidores de adn girasa y topoisomerasa iv; composicion farmaceutica; y su uso en tratamiento de infecciones bacterianas como neumonia adquirida intrahospitalariamente, infecciones a la piel, bronquitis, sinusitis, entre otras enfermedades.
WO2009156966A1 (en) 2008-06-25 2009-12-30 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
US20100317624A1 (en) 2009-06-08 2010-12-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
AR077971A1 (es) 2009-08-26 2011-10-05 Astrazeneca Ab Derivados heterociclicos de urea y metodos de uso de los mismos
BR112012024705A2 (pt) 2010-03-31 2016-06-07 Actelion Pharmaceuticals Ltd derivados antibacterianos de isoquinolin-3-ilureia

Also Published As

Publication number Publication date
ZA201308049B (en) 2016-08-31
CN103476756A (zh) 2013-12-25
MX2013011253A (es) 2013-10-17
MA35048B1 (fr) 2014-04-03
NZ617068A (en) 2015-05-29
TW201249801A (en) 2012-12-16
BR112013024899A2 (pt) 2016-12-20
CA2828423A1 (en) 2012-10-04
EP2691373A1 (en) 2014-02-05
US8889676B2 (en) 2014-11-18
AU2012235706A1 (en) 2013-11-14
KR20140019423A (ko) 2014-02-14
IL228486A0 (en) 2013-12-31
US20140038961A1 (en) 2014-02-06
WO2012131588A1 (en) 2012-10-04
JP2014512352A (ja) 2014-05-22
RU2013147875A (ru) 2015-05-10

Similar Documents

Publication Publication Date Title
AR089768A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
ES2625256T3 (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
AR085195A1 (es) Metodo de tratamiento de cancer
NZ607794A (en) N-acylsulfonamide apoptosis promoters
AR082101A1 (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento
MY182539A (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
MD4425C1 (ro) Alcoxipirazoli în calitate de activatori ai guanilat-ciclazei solubile
NZ631419A (en) Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use
EA201591586A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
PH12014502597A1 (en) N-substituted benzamides and their use in the treatment of pain
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
RU2017126128A (ru) Конденсированные бициклические соединения для лечения заболевания
BR112013010552A2 (pt) derivado de piridina e agente medicinal
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
BR112014010420A2 (pt) inibidores de pak para o tratamento de distúrbios proliferativos celulares
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
AR084637A1 (es) Compuestos heterociclicos apropiados para el tratamiento de la dislipidemia
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal